NewLimit
Backed by
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Explore similar companies to NewLimit
Profluent
Grounded in nature, authored by AI.
Bindwell
Building better pesticides with AI.
Science
A brighter tomorrow enabled by neural engineering.
Chai Discovery
Engineering better molecules using AI.
Cradle
Engineer better proteins, faster.
Lila Sciences
Building scientific superintelligence.
Manifold Bio
Tissue-targeted medicines, designed in vivo.
Valthos
Next-generation biodefense.
Convoke
AI-native OS for drug development.